arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

MARAVAI LIFESCIENCES HOLDINGS, INC.

MRVI
$6.22 ▼ -0.04 (-0.56%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
25 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

MARAVAI LIFESCIENCES HOLDINGS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $910.8M
Dividend Yield
Revenue Growth 40.5%
Op. Margin -3.3%
ROIC -0.5%
FCF / Share $0.03
Trailing P/E
Price / Book 4.3x
FCF Yield 0.5%
Debt / Equity 1.14
info Valuation on last close. End-of-day price, Aug 7, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$65.84M
↑ +40.5%
Net Income Profit after all expenses
$-3.73M
↑ +87.5%
Operating Margin Operating profit as % of sales
-3.3%
↑ +97.2% 2th
FCF / Share Free cash flow per share
$0.03
↑ +123.1%
Long-Term Debt Long-term obligations
$241.01M
↓ -17.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
14
Financial Health
26
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters